These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Marder SR; Essock SM; Miller AL; Buchanan RW; Davis JM; Kane JM; Lieberman J; Schooler NR Schizophr Bull; 2002; 28(1):5-16. PubMed ID: 12047022 [TBL] [Abstract][Full Text] [Related]
5. How to manage in current treatment of schizophrenic patients. Loga S Psychiatr Danub; 2007 Dec; 19(4):359-61. PubMed ID: 18000489 [TBL] [Abstract][Full Text] [Related]
6. Advantages and limitations of newer antipsychotics: evidence from large comparative trials. Jarskog LF Clin Schizophr Relat Psychoses; 2012 Oct; 6(3):113-4. PubMed ID: 23006235 [No Abstract] [Full Text] [Related]
7. CATIE and CUtLASS: can we handle the truth? Lewis S; Lieberman J Br J Psychiatry; 2008 Mar; 192(3):161-3. PubMed ID: 18310570 [TBL] [Abstract][Full Text] [Related]
8. Evidence-based psychiatry: outcomes and decisions. Meyer JM South Med J; 2007 Sep; 100(9):861-2. PubMed ID: 17902282 [No Abstract] [Full Text] [Related]
9. Half-full but nearly empty: implications of the schizophrenia PORT updated treatment recommendations. Hall LL Schizophr Bull; 2004; 30(3):619-21. PubMed ID: 15631254 [No Abstract] [Full Text] [Related]
10. [Antipsychotic agents are best chosen by their adverse effect profile]. Msghina M; Lindefors N Lakartidningen; 2009 Oct 28-Nov 3; 106(44):2841-2, 2844-6. PubMed ID: 19967963 [No Abstract] [Full Text] [Related]
11. Schizophrenia past clozapine: what works? Mustafa FA J Clin Psychopharmacol; 2013 Feb; 33(1):63-8. PubMed ID: 23277242 [TBL] [Abstract][Full Text] [Related]
12. Can clinical practice guide a research agenda? Marder SR Schizophr Bull; 2002; 28(1):127-9. PubMed ID: 12047012 [TBL] [Abstract][Full Text] [Related]
13. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042 [TBL] [Abstract][Full Text] [Related]
14. [Priority for atypical antipsychotic drugs? Current studies clarify the issues]. Dose M Psychiatr Prax; 2007 Jan; 34(1):46-9. PubMed ID: 17265252 [No Abstract] [Full Text] [Related]
15. Evidence-based pharmacotherapy of schizophrenia. Emsley R; Oosthuizen P Int J Neuropsychopharmacol; 2004 Jun; 7(2):219-38. PubMed ID: 15043765 [TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Lieberman JA Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808 [No Abstract] [Full Text] [Related]
17. Lessons from each drug trial. Marder SR Am J Psychiatry; 2007 Mar; 164(3):375-6. PubMed ID: 17329457 [No Abstract] [Full Text] [Related]
18. Selecting antipsychotics in schizophrenia: lessons from CATIE. Haddad P; Dursun SM J Psychopharmacol; 2006 May; 20(3):332-4. PubMed ID: 16574710 [No Abstract] [Full Text] [Related]
19. Famotidine augmentation in schizophrenia: hope or hype? Andrade C J Clin Psychiatry; 2013 Sep; 74(9):e855-8. PubMed ID: 24107771 [No Abstract] [Full Text] [Related]
20. Switch or stay? Davis JM; Marder SR; Tamminga CA Am J Psychiatry; 2006 Dec; 163(12):2032-3. PubMed ID: 17151147 [No Abstract] [Full Text] [Related] [Next] [New Search]